April 16, 2015 – ROCHESTER, NY – The team behind Clinical Conductor CTMS recently debuted new functionality that allows healthcare organizations to better manage adaptive and dynamic clinical research that is becoming more relevant in the industry every year. Included in this quarter’s release is functionality that lets users create snapshots of past budgets to be used for better negotiations and invoicing, the ability for organizations to create multiple charge masters, and functionality that provides better handling of protocol amendments. When added into the existing functionality of Clinical Conductor, users are afforded the unique opportunity to track and manage their complex and changing research with an unparalleled level of granularity.
With budget snapshots, researchers are able to create multiple versions of a study’s budget within Clinical Conductor. This gives users the ability to utilize historical budgets during negotiations with sponsors and CROs, track budget changes as a study progresses and keep better historical records that can be referenced during a post-study analysis or for future study preparation. With budget snapshots, the clearer financial picture allows organizations to maximize study budget utilization benefits.
The ability to create and manage multiple charge masters within Clinical Conductor allows organizations to manage complex billing requirements for trials that occur at multiple locations or over a long period of time. In the system, users can now reference multiple charge masters for each study, accounting for the location and time-period in which a procedure was conducted. As yearly cost updates are implemented, they are easily incorporated into ongoing studies, yielding greater accuracy in the assessment of the profitability of an individual study or an entire organization. What’s more, multiple charge masters make it easier to differentiate between grant and industry funding.
Clinical Conductor is also fitted with advanced protocol management functionality. Already the leading CTMS vendor in the industry, the added protocol functionality lets users more easily handle protocol amendments, create multiple versions of protocols and tie them directly to specific patients, ensuring subjects receive the correct procedures at all times. Researchers managing both oncology and long-term observational studies also benefit from the ability to manage investigator-initiated protocols more effectively.
“As research becomes more complex, and organizations partner or consolidate, businesses constantly look for ways to overcome the changing hurdles that inevitably occur during the study process, and technology is steadily becoming the solution to these hurdles,” stated Bio- Optronics VP and COO Jeff Markin. “Beyond that, of any other CTMS application, Clinical Conductor continually advances evolves to provide research organizations with flexible trial management functionality that allows them to conduct studies with relative ease in a compliant, profitable manner.”
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.